Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 4 3Phase 2/3 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × OTHER × Toremifene × Clear all
NCT02344940 2019-09-24

TTOS

Shanghai Jiao Tong University School of Medicine

Phase 4 Completed
104 enrolled
Breast

Breast Neoplasms

NCT03238703 2018-12-27

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Fred Hutchinson Cancer Center

Phase 4 Withdrawn
Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT02089854 2016-12-02

AETNBC

Peking Union Medical College Hospital

Phase 4 Unknown
800 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡